From the Journals

Liver enzyme a marker of disease progression in primary biliary cholangitis


 

REPORTING FROM SCIENTIFIC REPORTS


Based on their findings, the researchers concluded that serum ATX levels “represent an accurate, noninvasive biomarker for estimating disease progression in patients with PBC.”

However, they said a longer longitudinal study of patients with PBC looking at ATX levels and clinical features, as well as long-term prognosis and complicating hepatocellular carcinoma, was warranted.

Two coauthors are employees of TOSOH corporation and Inova Diagnostics. The remaining authors had no conflicts to declare related to this study.

SOURCE: Joshita S et al. Scientific Reports. 2018 May 25. doi: 10.1038/s41598-018-26531-0.

Pages

Recommended Reading

Treatment of HCV in special populations
MDedge Internal Medicine
New drugs provide new options in HCC
MDedge Internal Medicine
Class III obesity increases risk of acute on chronic liver failure in cirrhotic patients
MDedge Internal Medicine
Where the latest HCV drug combos fit in
MDedge Internal Medicine
How to choose between highly effective HBV therapies
MDedge Internal Medicine
Liver transplantation is on the rise for patients with severe alcoholic hepatitis
MDedge Internal Medicine
Scoring system quantified chances of HCV treatment benefit
MDedge Internal Medicine
NAFLD patients with abnormal liver tests may not get statins when indicated
MDedge Internal Medicine
Multiple therapies for NAFLD and NASH are now in phase 3 clinical trials
MDedge Internal Medicine
VIDEO: Hepatitis C eradication cuts nonliver cancer rate
MDedge Internal Medicine